Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Improving ECG data collection and analysis using high-tech equipment

Our core lab is situated at our clinical unit at London Bridge, offering a focused work environment for TQT trials with no additional costs, thereby delivering value for money to pharmaceutical sponsors.

We use FDA compliant MAC 2000 resting ECGs and Digital12-Lead Holter devices for collection, transmission and processing of digital ECG and Holter recordings for TQT studies. Each bedside has a GE MAC 2000, 12-lead ECG machine connected to the MUSE® Server allowing for storage of thousands of digital ECG’s. These digitised ECG's are available to our cardiological sciences team as required for subsequent digitised reading, analysis and reporting. The system is FDA 21 CFR Part 11 compliant with secure authorized user access and password protection to allow access to users for their required access levels only. A detailed audit trail is available and includes the username, date and time of access of any individual using the system and what addition or change they made to the database.

The digital 12-Lead ECG machines used for our studies are configured to ensure every ECG data file contains the exact and correct information in FDA compliant format (HL7) as per ICH E14. The configuration of each machine used in our TQT studies undergoes a vigorous validation process, including acquisition and transfer of test ECGs from the machine’s simulator. The standard configuration and validation process is fully documented and available to clients upon request.

Producing data you can trust, using the latest equipment.

Get in touch today

Latest news

Samarjit Singh promoted to New Director of Clinical Operations

August 30, 2022
Richmond Pharmacology is delighted to announce the promotion of Samarjit Singh into the position of Director of Clinical Operations.
Read more

Transforming clinical trials to accelerate drug development – Keith Berelowitz

August 23, 2022
Dr Keith Berelowitz, Richmond Pharmacology’s Director of Operations, wrote recently for Pharmaceutical Market Europe where he outlined how innovations in the design and delivery of clinical trials are speeding up the discovery of new therapies for the benefit of patients, sponsors and health systems.
Read more

Events

The Future of Healthcare - March 2022

13:30 – 16:00, 22nd March 2022
Discover the intricacies of assessing abnormal liver functions in clinical trial volunteers and gain insights from the latest drug development trials using RNAi therapeutics.
View event